Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma
PHASE2CompletedINTERVENTIONAL
Timeline
Start Date
January 31, 2003
Study Completion Date
June 30, 2004
Conditions
Lymphoma
Interventions
BIOLOGICAL
aldesleukin
BIOLOGICAL
rituximab
Trial Locations (1)
10021
Memorial Sloan-Kettering Cancer Center, New York
All Listed Sponsors
collaborator
National Cancer Institute (NCI)
NIH
lead
Memorial Sloan Kettering Cancer Center
OTHER
NCT00059904 - Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter